@dengyuemedicine.bsky.socialSame drug. New shape. Big difference for patients.
China's NMPA just approved a tablet version of selpercatinib (Retevmo) — the world's first highly selective RET inhibitor with CNS activity — expanding on its 2022 capsule approval. 🧪
@lcrf.orgOur grateful thanks to Endeavor Health for sponsoring the Free to Breathe Chicago Walk! #FreeToBreathe #LungCancer #ThankYou
@lcrf.orgWe're only one week away from the Free to Breathe Kansas City Walk! Come and be part of the movement to support #LungCancer research on Saturday, Sept 26. We can't wait to see you! Sign up at lcrf.org/kc.
@samillingworth.com🧬 One gene variant raises lung cancer risk
A US study of more than 3.3 million people linked the EGFR T790M gene variant to lung cancer risk, with no link to 17 other cancers. Matters for families with lung cancer.
@lcrf.orgOur grateful thanks to Howell Family Dentistry for sponsoring the Free to Breathe Kansas City Walk! #FreeToBreathe #LungCancer #ThankYou
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: Where now? The Future of Interventional Bronchoscopy presented by Ricky Thakrar. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@lcrf.orgWhat raising funds for research via the Free to Breathe Walk means to Valerie: “Research means finding a cure for lung cancer, and finding treatments that do more harm to cancer and less harm to the rest of the body. It means saving lives.” #LungCancer #ButterflySummer lcrf.org/anywhere
@onc-rg.bsky.social
@onc-rg.bsky.socialJoin our team as we break down the major readouts from WCLC 2026 and discuss what key signals to watch for as we head into ESMO 2026!
Register: events.teams.microsoft.com/event/681070...
@kill-bait.bsky.socialInherited EGFR mutation sharply increases lung cancer risk, especially in Southern Appalachia
🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅
#lungcancer #egfrmutation #geneticrisk
👇👇👇
@frederikhermann.comToday's @science.org cover: a rare inherited variant that raises #lungcancer odds 25x, ~60x in people who never smoked.
#23andMe + @danafarber.bsky.social found 641 carriers in 10M+ participants and traced it to an 1800s founder event in Southern Appalachia.
@sinclaircri.bsky.socialCongrats to all including Dozie Ubosi 🎉 - a grad student & flash‑talk presenter at our recent Annual Retreat, supervised by our @sinclaircri.bsky.social associate member Dr. Xian Wang & Dr. Yongjun Lai #SmithEngQueens - on receiving a Research Training Award. Well done! #LungCancer #CancerResearch
@vcclibrary.bsky.socialPatient-reported symptom monitoring in patients with #LungCancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial. www.thelancet.com/journals/lan...
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: Physician-led, point of care genomic testing in the lung cancer pathway presented by Matthew Evison. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@vcclibrary.bsky.socialTambotatug Pelitecan in Small-Cell #LungCancer after Platinum-Based Therapy. www.nejm.org/doi/full/10....
@vcclibrary.bsky.socialTambotatug Pelitecan in Small-Cell #LungCancer after Platinum-Based Therapy. www.nejm.org/doi/full/10....
@cancers-mdpi.bsky.social🧬Spatial #Transcriptomics in #LungCancer and Pulmonary Diseases: A Comprehensive Review
🧑🔬by Da Hyun Kang, Yoonjoo Kim et al. from Chungnam National University
📊Cited 19 times!
Read it here🔗 www.mdpi.com/2072-6694/17...
#SpatialTranscriptomics #PulmonaryDisease #TumorMicroenvironment
@lungcancereurope.bsky.socialThis week, Germany announced a new network to help deliver #lungcancer screening in practice.
The network links 25 radiology screening sites with specialist second-reading centres in Heidelberg, supporting consistent reporting and follow-up.
Screening is about delivery as well as policy. #LCSM
@alkpositiveuk.bsky.socialCould alectinib be used before surgery for ALK+ #lungcancer?
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
@lcrf.orgEvery #WomenWednesday, we are spotlighting women who are making a difference in the lung cancer community – in labs, at hospitals, and by sharing their stories.
Nadia tells about the women she lost to #LungCancer – and why she champions research for all the parients who deserve more time.